✦ LIBER ✦

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

✍ Scribed by Michael Poyurovsky; Danny Koren; Inna Gonopolsky; Michael Schneidman; Camil Fuchs; Abraham Weizman; Ronit Weizman

Book ID: 119575750
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 69 KB
Volume: 13
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(02)00155-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of ritanserin, a 5HT2A/2C antagon

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study

✍ Shahin Akhondzadeh; Mojgan Malek-Hosseini; Aboulfazl Ghoreishi; Maedeh Raznahan; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 422 KB

Effects on migraine headache of MDL72,22

Effects on migraine headache of MDL72,222, an antagonist at neuronal 5-HT receptors. Double-blind, placebo-controlled study

✍ Levin, Harry 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Granisetron as an add-on to risperidone

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study

✍ Khodaie-Ardakani, Mohammad-Reza; Seddighi, Sahar; Modabbernia, Amirhossein; Reza 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 368 KB

EFFECTS OF ADD-ON MIRTAZAPINE ON NEUROCO

EFFECTS OF ADD-ON MIRTAZAPINE ON NEUROCOGNITION IN SCHIZOPHRENIA: AN OPEN LABEL EXTENSION PHASE OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, AND BOTH PHASES

✍ Jan H. Stenberg; Viacheslav Terevnikov; Marina Joffe; Jari Tiihonen; Evgueni Tch 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 66 KB

The effect of famotidine addition on ola

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

✍ Michael Poyurovsky; Vered Tal; Rachel Maayan; Irit Gil-Ad; Camil Fuchs; Abraham 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 96 KB

No Effect of the Calcium Antagonist, Isr

No Effect of the Calcium Antagonist, Isradipine, on Plasma Catecholamines in Irreversible Chronic Obstructive Pulmonary Disease (COPD). A Randomized, Double-blind, Placebo-controlled Study

✍ Niels A. Graudal; Anders M. Galløe; Inger Plum; Nils Milman; Jesper O. Clausen 📂 Article 📅 1995 🏛 Elsevier 🌐 English ⚖ 243 KB

SUMMARY: Calcium antagonists have been claimed to decrease the pulmonary artery pressure and increase oxygen uptake and cardiac output in patients with chronic obstructive pulmonary disease (COPD). This should tend to decrease the plasma levels of catecholamines. The purpose of the present study was